FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry and concerns an agent possessing neuroprotective action representing prostamide of formula 
(1) which can find application in medicine in therapy of ischemic cerebral damages and neurodegenerative diseases.
EFFECT: composition shows high efficacy.
16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROSTAGLANDIN DERIVATIVES HAVING ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY | 2015 |
|
RU2568603C1 |
| DERIVATIVES OF NON-STEROID ANTI-INFLAMMATORY AGENTS | 2018 |
|
RU2732297C2 |
| PROSTAGLANDIN FALPHA DERIVATIVES FOR REDUCING INTRAOCULAR PRESSURE | 2018 |
|
RU2718744C2 |
| PROSTAGLANDIN/CYCLOOXYGENASE PATHWAY MODULATION | 2007 |
|
RU2448712C2 |
| PHARMACEUTICAL COMPOSITION AND SET FOR TREATMENT OF REDUCED OSSEOUS MASS (VERSIONS) | 1996 |
|
RU2190395C2 |
| NEW COMPOUNDS AS mPGES-1 INHIBITORS | 2018 |
|
RU2793330C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| METHOD OF PREDICTING MISCARRIAGE IN THE FIRST TRIMESTER BY ASSESSING CYCLOOXYGENASE 2 AND PROSTAGLANDIN E2 IN THE PERIPHERAL BLOOD OF PREGNANT WOMEN DURING EXACERBATION OF CYTOMEGALOVIRUS INFECTION | 2023 |
|
RU2800080C1 |
| METHOD OF EARLY PREDICTION OF MISCARRIAGE BY ASSESSING INTERLEUKIN 1Β AND PROSTAGLANDIN E2 IN THE BLOOD SERUM OF PREGNANT WOMEN WITH EXACERBATION OF CYTOMEGALOVIRUS INFECTION | 2023 |
|
RU2804278C1 |
| METHOD OF HEAMATOPOIETIC STEM CELL GROWTH MODULATION | 2007 |
|
RU2425876C2 |
